Leptin and biochemical markers of bone turnover in dialysis patients

Journal of Nephrology

Volumn 17, Issue 2, 2004, Pages 253-260

  Zoccali, Carmine ^a   Panuccio, Vincenzo ^a   Tripepi, Giovanni ^a   Cutrupi, Sebastiano ^a   Pizzini, Patrizia ^a   Mallamaci, Francesca ^a  

^a CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Bone turnover; Dialysis; Leptin; PTH; Renal failure

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; CALCIUM; LEPTIN; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PHOSPHATE;

ADULT; AGED; ARTICLE; BODY MASS; BONE TURNOVER; CARBOXY TERMINAL SEQUENCE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HEMODIALYSIS; HORMONE BLOOD LEVEL; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE REMODELING; DIALYSIS; FEMALE; HUMANS; LEPTIN; MALE; MIDDLE AGED; PARATHYROID HORMONE; SEX FACTORS;

EID: 2942630768     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Mantzoros CS. The role of leptin in human obesity and disease: A review of current evidence. Ann Intern Med 1999; 130: 671-80.
2. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100: 197-207.
3. Gordeladze JO, Reseland JE. A unified model for the action of leptin on bone turnover. J Cell Biochem 2003; 88: 706-12.
4. Whipple T, Sharkey N, Demers L, Williams N. Leptin and the skeleton. Clin Endocrinol 2002; 57: 701-11.
5. Ormarsdottir S, Ljunggren O, Mallmin H, Olofsson H, Blum WF, Loof L. Inverse relationship between circulating levels of leptin and bone mineral density in chronic liver disease. J Gastroenterol Hepatol 2001; 16: 1409-14.
6. Leidig-Bruckner G, Ziegler R. Diabetes mellitus a risk for osteoporosis? Exp Clin Endocrinol Diabetes 2001; 109 (suppl 2): S493-514.
7. Sherrard DJ. Aplastic bone: a non disease of medical progress. Adv Ren Replace Ther 1995; 2: 20-3.
8. Cannata-Andia JB. Hypokinetic azotemic osteodystrophy. Kidney Int 1998; 54: 1000-16.
9. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH. Improved assessment of bone turnover by the PTH-(1-84) /large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60: 1460-8.
10. Navarro JF, Mora C, Jimenez A, Torres A, Macia M, Garcia J. Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients. Am J Kidney Dis 1999; 34: 43-8.
11. Jehle PM, Ostertag A, Schulten K, Schulz W, Jehle DR, Stracke S. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy. Kidney Int 2000; 57: 423-36.
12. Panuccio V, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Asahi K. Low parathyroid hormone and pentosidine in hemodialysis patients. Am J Kidney Dis 2002; 40: 810-15.
13. Caro JF, Besarab A, Burke JF, Glennon JA. A possible role for propranolol in the treatment of renal osteodystrophy. Lancet 1978; 2: 451-4.
14. Merabet E, Dagogo-Jack S, Coyne DW, Klein S, Santiago JV, Hmiel SP, Landt M. Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab 1997; 82: 847-50.
15. Sharma K, Considine RV, Michael B, Dunn SR, Weisberg LS, Kurnik BR. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997; 51: 1980-5.
16. Howard JK, Lord GM, Clutterbuck EJ, Ghatei MA, Pusey CD, Bloom SR. Plasma immunoreactive leptin concentration in end-stage renal disease. Clin Sci 1997; 93: 119-26.
17. Heimburger O, Lonnqvist F, Danielsson A, Nordenstrom J, Stenvinkel P. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 1997; 8: 1423-30.
18. Young GA, Woodrow G, Kendall S, Oldroyd B, Turney JH, Brownjohn AM, Smith MA. Increased plasma leptin/fat ratio in patients with chronic renal failure: a cause of malnutrition? Nephrol Dial Transplant 1997; 12: 2318-23.
19. Dagogo-Jack S, Ovalle F, Landt M, Gearing B, Coyne DW. Hyperleptinemia in patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 1998; 18: 34-40.
20. Nishizawa Y, Shoji T, Tanaka S, Yamashita M, Morita A, Emoto M. Plasma leptin level and its relationship with body composition in hemodialysis patients. Am J Kidney Dis 1998; 31: 655-61.
21. Kokot F, Wiecek A, Mesjasz J, Adamczak M, Spiechowicz U. Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients. Nephrol Dial Transplant 1998; 13: 1200-5.
22. Nordfors L, Lonnqvist F, Heimburger O, Danielsson A, Schalling M, Stenvinkel P. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 1998; 54: 1267-75.
23. Stamatiadis DN, Chan JL, Cogswell R, Stefanopoulou HC, Bullen J, Katsilambros N, Stathakis CP, Mantzoros CS. Elevated leptin fragments in renal failure correlate with BMI and haematopoiesis and are normalized by haemodialysis. Clin Endocrinol (Oxf) 2004; 60: 434-41.
24. Johansen KL, Mulligan K, Tai V, Schambelan M. Leptin, body composition, and indices of malnutrition in patients on dialysis. J Am Soc Nephrol 1998; 9: 1080-4.
25. Clausen P, Nielsen PK, Olgaard K, Feldt-Rasmussen B. The plasma leptin concentration is closely associated with the body fat mass in nondiabetic uremic patients. Am J Nephrol 1999; 19: 485-91.
26. Fontan MP, Rodriguez-Carmona A, Cordido F, Garcia-Buela J. Hyperleptinemia in uremic patients undergoing conservative management, peritoneal dialysis, and hemodialysis: A comparative analysis. Am J Kidney Dis 1999; 34: 824-31.
27. Widjaja A, Kielstein JT, Horn R, von zur Muhlen A, Kliem V, Brabant G. Free serum leptin but not bound leptin concentrations are elevated in patients with end-stage renal disease. Nephrol Dial Transplant 2000; 15: 846-50.
28. Yoneda T, Maruyama Y, Uji Y, Motomiya Y, Hashiguchi Y, Miura M. A possible role for leptin in normo- or hypoparathyroid uremic bone in postmenopausal dialysis women. J Bone Miner Metab 2001; 19: 119-24.
29. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis 2002; 39: 1-11.
30. Kokot F, Chudek J, Karkoszka H, Adamczak M, Wiecek A, Klimek D. Does PTH influence leptin concentration in haemodialysed uraemic patients? Nephron 1999; 82: 372-3.
31. Coen G, Ballanti P, Bonucci E, Calabria S, Centorrino M, Fassino V. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 2294-302.
32. Himms-Hagen J. Physiological roles of the leptin endocrine system: differences between mice and humans. Crit Rev Clin Lab Sci 1999; 36: 575-655.
33. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-41.
34. Chudek J, Adamczak M, Kokot F, Karkoszka H, Ignacy W, Klimek D, Wiecek A. Relationship between body composition, sex hormones and leptinemia in hemodialyzed patients with chronic renal failure. Clin Nephrol 2002; 58: 431-7.
35. Gordeladze JO, Drevon CA, Syversen U, Reseland JE. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: Impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem 2002; 85: 825-36.
36. Kramer HM, Curhan GC, Singh A. Permanent cessation of menses and postmenopausal hormone use in dialysis-dependent women: the HELP study. Am J Kidney Dis 2003; 41: 643-50.
37. Lim VS, Henriquez C, Sievertsen G, Frohman LA. Ovarian function in chronic renal failure: evidence suggesting hypothalamic anovulation. Ann Intern Med 1980; 93: 21-7.
38. Fernandez-Real JM, Vayreda M, Casamitjana R, Gonzalez-Huix F, Ricart W. The fat-free mass compartment influences serum leptin in men. Eur J Endocrinol 2000; 142: 25-9.
39. Mallamaci F, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tripepi R, Zoccali C. Gender-dependent differences in plasma leptin in essential hypertension. Am J Hypertens 2000; 13: 914-20.
40. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26: 622-31.
41. Coen G, Ballanti P, Fischer MS, Balducci A, Calabria S, Colamarco L, Di Zazzo G, Lifrieri F, Manni M, Sardella D, Nofroni I, Bonucci E. Serum leptin in dialysis renal osteodystrophy. Am J Kidney Dis 2003; 42: 1036-42.
42. Goodman WG, Juppner H, Salusky IB, Sherrard DJ. Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Kidney Int 2003; 63: 1-11.
43. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-21.